Protherics UK Ltd, BTG plc’s manufacturing facility in Ceredigion, west Wales is pleased to announce that the facility has been awarded Level 5 of the Green Dragon Environmental Standard following an independent audit of its environmental policies and procedures by Groundwork Wales, a UKAS Accredited Inspection Body.
The Protherics UK Ltd manufacturing facility in Wales plays an important role on the manufacture of CroFab® (crotalidae polyvalent immune fab (ovine)) and DigiFab® (digoxin immune fab (ovine)), two of BTG’s specialty pharmaceutical acute care antidotes, used in the hospital setting to treat serious medical toxicities.
Green Dragon is a stepped Standard, recognising effective environmental management. It offers an environmental management system relevant to the specific needs of companies and organisations and rewards actions taken to achieve environmental improvements. There are five levels within the Green Dragon Standard, with Level 5 the highest level, with each step contributing towards achievement of the International and European Environmental Standards ISO 14001 and EMAS. Further information about Groundwork Wales and the Green Dragon Environmental Standard can be found at wales.groundwork.org.uk.
Sam Jenkinson, Site Director at Protherics UK Ltd, commented on the award “BTG has always taken its responsibility for Environmental, Health & Safety very seriously and seeks to ensure that health & safety and environmental factors are key considerations in everything that we do. The award of the Green Dragon Level 5 Standard, together with the British Safety Council 5 Star Award for Health & Safety which we received last year demonstrates that our activities in this area are being recognised and my colleagues in Wales should feel proud of this excellent achievement.”
BTG: Ashley Tapp, Communications Manager
T: +44(0)20 7575 1513 / M: +44(0)77 9081 1554
BTG (btgplc.com) is a growing international specialist healthcare company that is developing and commercialising products targeting acute care, cancer and vascular diseases. The company has diversified revenues from sales of its own marketed products and from royalties on partnered products, and is seeking to acquire new programmes and products to develop and market to specialist physicians.